Novonesis Future Growth

Future criteria checks 0/6

Novonesis is forecast to grow earnings and revenue by 1.1% and 1.6% per annum respectively. EPS is expected to grow by 21.4% per annum. Return on equity is forecast to be 8.1% in 3 years.

Key information

1.1%

Earnings growth rate

21.4%

EPS growth rate

Chemicals earnings growth	20.0%
Revenue growth rate	1.6%
Future return on equity	8.1%
Analyst coverage	Good
Last updated	18 Nov 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Earnings and Revenue Growth Forecasts

CPSE:NSIS B - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	3,045	283	598	891	N/A
3/31/2024	2,696	332	486	779	N/A
12/31/2023	2,401	406	281	557	N/A
9/30/2023	2,390	430	169	485	N/A
6/30/2023	2,382	460	83	436	N/A
3/31/2023	2,390	487	83	476	N/A
12/31/2022	2,360	494	150	539	N/A
9/30/2022	2,268	460	206	554	N/A
6/30/2022	2,186	418	262	539	N/A
3/31/2022	2,090	416	337	530	N/A
12/31/2021	2,009	423	379	546	N/A
9/30/2021	1,958	427	461	593	N/A
6/30/2021	1,914	409	432	564	N/A
3/31/2021	1,883	389	443	577	N/A
12/31/2020	1,883	380	459	585	N/A
9/30/2020	1,920	415	442	521	N/A
6/30/2020	1,955	405	465	536	N/A
3/31/2020	1,968	439	407	482	N/A
12/31/2019	1,924	422	352	428	N/A
9/30/2019	1,923	411	316	460	N/A
6/30/2019	1,917	434	350	505	N/A
3/31/2019	1,922	417	309	477	N/A
12/31/2018	1,927	432	306	493	N/A
9/30/2018	1,924	427	303	515	N/A
6/30/2018	1,915	429	262	490	N/A
3/31/2018	1,920	423	N/A	501	N/A
12/31/2017	1,952	419	N/A	546	N/A
9/30/2017	1,958	421	N/A	533	N/A
6/30/2017	1,934	412	N/A	522	N/A
3/31/2017	1,919	414	N/A	547	N/A
12/31/2016	1,902	410	N/A	517	N/A
9/30/2016	1,864	394	N/A	488	N/A
6/30/2016	1,883	394	N/A	437	N/A
3/31/2016	1,883	384	N/A	450	N/A
12/31/2015	1,876	378	N/A	447	N/A
9/30/2015	1,840	366	N/A	395	N/A
6/30/2015	1,795	353	N/A	443	N/A
3/31/2015	1,741	340	N/A	454	N/A
12/31/2014	1,673	339	N/A	608	N/A
9/30/2014	1,641	334	N/A	680	N/A
6/30/2014	1,605	324	N/A	643	N/A
3/31/2014	1,598	319	N/A	567	N/A
12/31/2013	1,575	295	N/A	348	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NSIS B's forecast earnings growth (1.1% per year) is below the savings rate (1.2%).

Earnings vs Market: NSIS B's earnings (1.1% per year) are forecast to grow slower than the Danish market (11.6% per year).

High Growth Earnings: NSIS B's earnings are forecast to grow, but not significantly.

Revenue vs Market: NSIS B's revenue (1.6% per year) is forecast to grow slower than the Danish market (10% per year).

High Growth Revenue: NSIS B's revenue (1.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NSIS B's Return on Equity is forecast to be low in 3 years time (8.1%).

Novonesis Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novonesis Provides Earnings Guidance for the Year 2024

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022